focus -WSS

focus

author：comprehensive 2025-09-02 03:53:14 - browse：6836

SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and reviewed by STAT.

The layoffs, which began last Wednesday, impact research teams across the company’s California sites in San Diego and Foster City, as well as locations in Madison, Wisconsin; Singapore; and the United Kingdom. Alex Aravanis, the company’s chief technology officer, noted in an internal message that these cuts affect a tenth of research and development staff. The company’s also planning to shut down all lab-based research and development work in Foster City, according to a note from Steve Barnard, vice president of technology development.

Barnard’s note mentions that all affected employees have already been notified. And a separate message from interim CEO Charles Dadswell makes clear last week’s layoffs won’t be the last.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Listen: Biogen's potential pivot, & Illumina's next chapter

WSS

An Ebola outbreak presents a new mystery involving children

Wegovy cuts risk of cardiovascular events by 20%, study finds

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

NIH nominee Bertagnolli will get October confirmation hearing

Astronauts get first look at the spacecraft that will fly them around the moon

NIH nominee Bertagnolli will get October confirmation hearing

explore

focus

leisure time

Walensky prepares to leave CDC — and Congress — behind

Listen: Biogen's potential pivot, & Illumina's next chapter

Moonlake's readout produced a cash windfall. Risks remain

Astronauts get first look at the spacecraft that will fly them around the moon

Alkermes shareholders re

'Make People Better': The CRISPR babies story you probably don't know

Sports medicine is finally prioritizing gender equality

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

United colonoscopy coverage change 'may cost lives,' doctors say

Snackable artificial intelligence, expert AI, and the pharma industry

hotspot

House transparency, PBM reform bill gains bipartisan support

How generative AI is inspiring dreams of a health data revolution

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Advances in CAR

Illumina names Agilent executive as new CEO

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

focus

entertainment

knowledge

knowledge